Skip to content

Dianthus Therapeutics

US · DNTH #2155 by market cap Listed 1970
84.55 -0.28 -0.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Valuation each multiple against its own 5-year range

P/B ratio 4.16 Expensive vs history 85th percentile
5-year average 1.91 · #361 of 514 in Biotechnology
P/E ratio -22.50 Cheap vs history 6th percentile
5-year average -7.21 · forward -21.65
P/S ratio 1,902.16 Expensive vs history 87th percentile
5-year average 517.12 · forward 3,186.88 · #361 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Dianthus Therapeutics (DNTH) 4.76B -20.72 3.84 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★☆ Fair value113.44 Economic moatNone UncertaintyHigh

Trading 34.2% below Morningstar's fair value estimate.

Fair value

Dianthus Therapeutics Inc earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 19% discount to our quantitative fair value estimate of $113.44 per share; however, caution is warranted due to this estimate's high uncertainty rating.

We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:59:44 · For reference only, not investment advice and not tailored to your situation.

Dianthus Therapeutics discussion 0 comments

Add a comment